Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env
Authors:
- Manuel ColladoManuel Collado
- Dolores Rodrı́guezDRDolores Rodrı́guez
- Juan Ramón Rodrı́guezJRJuan Ramón Rodrı́guez
- Isabel VázquezIVIsabel Vázquez
- Rosa M. GonzaloRGRosa M. Gonzalo
- Mariano EstebanMEMariano Esteban
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Applications of pox virus vectors to vaccination: an update.Proceedings of the National Academy of Sciences, 1996
- Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.Proceedings of the National Academy of Sciences, 1996
- Memory Cytotoxic T Lymphocyte Responses in Human Immunodeficiency Virus Type 1 (HIV-1)-Negative Volunteers Immunized with a Recombinant Canarypox Expressing gp160 of HIV-1 and Boosted with a Recombinant gp160The Journal of Infectious Diseases, 1996
- Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Cytolytic T Lymphocyte Responses in Seronegative Adults by a Nonreplicating, Host-Range-Restricted Canarypox Vector (ALVAC) Carrying the HIV-1MN env GeneThe Journal of Infectious Diseases, 1995
- A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)AIDS Research and Human Retroviruses, 1995
- Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated BoostingThe Journal of Infectious Diseases, 1994
- Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.Proceedings of the National Academy of Sciences, 1993
- Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive AdultsThe Journal of Infectious Diseases, 1993
- Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses.Proceedings of the National Academy of Sciences, 1989
- Expression of the HTLV-III envelope gene by a recombinant vaccinia virusNature, 1986